LAVA Therapeutics
LVTX
LVTX was delisted on the 20th of November, 2025.
22 hedge funds and large institutions have $6.15M invested in LAVA Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
10.9% more ownership
Funds ownership: 13.73% → 24.62% (+11%)
5% more funds holding
Funds holding: 21 → 22 (+1)
3% more capital invested
Capital invested by funds: $5.99M → $6.15M (+$164K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$65.6K |
| 2 |
EGM
Engineers Gate Manager
New York
|
+$31.6K |
| 3 |
HF
HRT Financial
New York
|
+$28K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$27.3K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$20.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWG
Alpha Wave Global
New York
|
-$145K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$88.1K |
| 3 |
Two Sigma Investments
New York
|
-$84.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$80K |
| 5 |
Two Sigma Advisers
New York
|
-$44.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Citadel Advisors
Miami,
Florida
| – | -$28.2K | -17,013 | Closed |
|
27
Walleye Capital
New York
| – | -$24.5K | -14,762 | Closed |
|
LVTX Hedge Fund Activity: Q4 2024 in Review
22 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q4 2024, worth a combined $6.15M — up 2.7% from $5.99M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LVTX positions and 7 closed out — a net gain of 1 holder — while 5 added to existing stakes and 3 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $65.6K. The largest seller was Alpha Wave Global, exiting entirely with an estimated $145K sold.
- 22 institutional investors held LAVA Therapeutics (LVTX) as of Q4 2024, up from 21 in Q3 2024.
- Funds reported $6.15M of LAVA Therapeutics stock for Q4 2024, up 2.7% quarter-over-quarter.
- 8 funds opened new LAVA Therapeutics positions in Q4 2024 and 7 closed out, a net change of +1 holder.
- The largest LAVA Therapeutics buyer in Q4 2024 was BNP Paribas Financial Markets, an estimated $65.6K added.
- The largest LAVA Therapeutics seller in Q4 2024 was Alpha Wave Global, an estimated $145K sold.
Based on aggregated 13F filings for Q4 2024.